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1. Introduction
Traumatic brain injury with associated intracranial bleeding is an emergency requiring diag‐
nostic and supportive measures directed at limiting subsequent morbidity and mortality. If
this intracranial bleeding is discovered in a patient that is anticoagulated, further aggressive
steps are indicated to reverse the effects of the anticoagulant and limit further bleeding.
Hematoma or bleeding volume & growth does correlate with various outcome measures
[1-3]. Following spontaneous ICH, hematoma expansion on follow-up neuroimaging is not‐
ed in as much as 26% of cases [1]. Particularly in anticoagulated patients, such hematoma
expansion is associated with poor outcomes [4]. Hemostatic therapy with agents directed at
trying to reverse the effects of the anticoagulant have been shown to potentially be effective
in reducing hematoma expansion in such patients [5,6]. Failing to correct a high INR, for ex‐
ample, may be associated with higher mortality [7]. Therefore, prompt recognition of this
condition and taking immediate action is important in treating traumatic intracranial hem‐
orrhage. There are more options than ever for providing systemic anticoagulation to pa‐
tients. These different agents work in different ways and have different pharmacokinetics
and pharmacodyanmics. Published data supporting specific strategies for reversing the ef‐
fects of these agents is limited, particularly for novel anticoagulants. However, the pharma‐
cology and mechanism of action of some anticoagulant therapies (outlined in Figure 1 &
Table 1) have led to at least initial studies that can provide some guidance.
© 2014 Tannehill; licensee InTech. This is a paper distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
Figure 1. The clotting cascade. The vitamin K dependant factors (green circled factors) are inhibited by warfarin. Fac‐
tor Xa is inhibited by rivaroxaban and apixaban. Dabigatran direrctly inhibits thrombin.
Medication Mechanism of Action T 1/2(hrs) Dose
Renal
dosing Excretion
Protein
Bound
Warfarin Vitamin K antagonist 20-60 2-10mgdaily None
92% urine
bile 99%
Rivaroxaban Direct factor Xa Inhibitor 5-13 10-30mgdaily Yes
66% urine
28% feces 92-95%
Apixaban Direct factor Xa Inhibitor 8-12 2.5-5mgBID Yes
27% urine
feces 87%
Dabigatran Direct thrombin inhibitor 12-17 110-150mgBID Yes 80% urine 35%
Table 1. Pharmacology of warfarin and the novel anticoagulants.
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2. Warfarin & strategies for warfarin-associated ICH
Studies suggest that hematoma expansion in patients anticoagulated with warfarin who suffer
an intracranial hemorrhage may be limited by quickly normalizing INR [8]. Mortality rates for
these patients may be as high as 66% for those with an INR > 3 [9]. Historically, clinicians have
used vitamin K and fresh frozen plasma (FFP) to treat warfarin-associated bleeding, including
ICH. Vitamin K is given to patients that have received warfarin so as to counteract the effects
of warfarin inhibiting the vitamin-K dependant gamma-carboxylation of coagulation factors
II, VII, IX and X and the anticoagulant factors protein C and S. Its time to maximum effective‐
ness can be measured in hours, so its use alone is not recommended [10]. FFP can be transfused
to replenish the lower levels of vitamin K dependant clotting factors in patients that have been
taking vitamin K antagonists. Recent data have led to a change in the American College of
Chest Physicians guidelines to recommend the use of four-factor prothrombin complex
concentrate to reverse the effects of warfarin in the treatment of major bleeding (Level 2C
evidence) [11]. FFP has fallen out of favor for multiple reasons. Firstly, it must be thawed and
this process can take anywhere from 20-60 minutes, causing the clinician to lose valuable time
in trying to reverse the patient’s coagulopathy. Additionally, FFP is given in a large weight-
based volume (as much as two to four L total) that may be unadvisable in certain patients [12].
Lastly, FFP is a blood product and it is widely recognized that blood product administration
in general and FFP specifically should be minimized as much as possible in the critically ill
patient. This is because of the associated risks of acute lung injury, transfusion-associated
circulatory overload, infection, etc [10, 68]. Additionally, it is quite common for FFP to be
transfused inappropriately, or at least outside the recommendations of published guidelines
[69].
Prothrombin complex concentrates (PCC) have been shown to normalize an elevated INR
within 10-30 minutes of administration [13]. Prothrombin complex concentrates (PCC) are a
group of products containing virus-reduced, concentrated, pooled plasma products made of
a combination of three or four vitamin K-dependant clotting factors [10]. There are two
versions commercially available, so-called three-factor and four-factor PCC. These agents have
varying concentrations of coagulation factors II (prothrombin), VII, IX and X. Factor VIII
Inhibitor Bypassing Activity, nonfiltered – or FEIBA NF – is an FDA approved four-factor PCC
that is a nanofiltered, vapor-heated freeze-dried sterile human plasma fraction [14]. Until
recently, it was the only four-factor complex available in the United States. As an activated
product, it may hold more thrombogenic potential, limiting its use. Introduced in the summer
of 2013, Kcentra (known as Beriplex P/N in Europe) is the only FDA-approved four-factor PCC
available in the United States [15].
The preference for four-factor PCC over the three factor formulations is because of the
increased concentration of factor VII in the four factor PCCs [11]. This may account for their
possible superior effectiveness at reversing warfarin-associated anticoagulation [16]. Nonac‐
tivated four-factor PCC has only recently been available in the United States [15]. Prior to this,
only FEIBA, an activated form of PCC was commercially available in the US. FEIBA has been
suggested as an option for reversing the effects of VKA, but there have been concerns that this
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agent may increase thrombogenesis.[11]. Another option was to use one of the available three-
factor PCCs, Profiline SD or Bebulin VH plus rVIIA, but this also comes with a similar
thrombogenic risk, particularly arterial thromboses [18,19]. Four-factor PCC is the recom‐
mended agent for warfarin reversal in acute, severe bleeding [11]. While there are no random‐
ized, controlled studies, there are multiple observational trials summarized by a systematic
review of 18 studies in 654 patients. This review suggested that 4-factor prothrombin complex
concentrates are more reliable for correcting the international normalized ratio (INR) com‐
pared with three factor formulations. This effect appears intact at least up until very elevated
INRs (>4) where the effectiveness may be less reliable for both the three and four factor PCC
[17]. While these agents are effective in reversing a high INR, it must be remembered that they
may infer a risk of thromboembolism [18]. However, recent studies comparing four-factor PCC
with FFP for urgent warfarin reversal seem to suggest that this adverse event rate - including
thromboembolism - is at least the same, if not better than with FFP [71, 72].
3. Non-warfarin anticoagulants and strategies for treating ICH
An important point to remember when treating a patient that is anticoagulated with dabiga‐
tran, rivaroxaban or apixaban is that the physiologic effect of these drugs is much shorter in
duration than that of warfarin. Warfarin can remain effective for up to 4 or 5 days as its half-
life may be as long as 38-42 hours or longer. The direct-thrombin inhibitor, dabigatran, has a
half-life of 12-17 hours. The factor Xa inhibitors, rivaroxaban (7-11hr) and apixaban (9-14hr)
have similar, considerably shorter half-lives than warfarin and therefore are eliminated from
the body more quickly. This elimination is somewhat dependant on renal function and
therefore adjustments must be made in awaiting clearance of the drug’s effect in patients with
renal dysfunction. [19-22]
3.1. Dabigatran
Dabigatran is an oral direct thrombin inhibitor approved for the reduction of stroke risk in
patients with nonvalvular atrial fibrillation. Maximum concentration is reached within about
one hour of ingestion and the drug is cleared renally [23]. Dabigatran was shown in the RE-
LY trial to be effective in the prevention of systemic embolism in non-valvular atrial fibrillation.
The United States Food and Drug Administration therefore approved it in 2010 for this
indication. The RE-LY study also demonstrated that dabigatran conferred a similar yearly rate
of major bleeding with warfarin of about 3% and life-threatening bleeding of about 1.5%. [24].
Renal clearance of dabigatran suggests a potential role for hemodialysis in reversing the effects
of this agent. [22].
FFP, however, will not reverse this agent, but rFVIIa may have a role [25]. In a murine model
of ICH, FFP was shown to decrease ICH volume in animals that had received high dose, but
not low dose, dabigatran. However, mortality remained higher in the mice that received high
dose dabigatran and FFP did not reduce mortality. Beriplex, a four-factor PCC, decreased ICH
hematoma size in both the high and low dose groups [26]. Other animal data in rabbits has
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suggested that PCC may be effective in reversing the anticoagulation effect of dabigatran [27].
There is a case report of FFP & PCC being used in combination to successfully treat dabigatran-
induced gastrointestinal bleeding; however, full confirmation of this association was difficult
because of patient comorbidities [28]. Similarly, FEIBA has been suggested in a case report as
a potential therapy for dabigatran-associated bleeding [29].
However, a four factor PCC had no positive effect on the anticoagulant activity of dabigatran
in a randomized, double-blind placebo controlled trial conducted by Eerenberg, et al. [30].
FEIBA at a lower than typical dose could have a role in reversing the anticoagulant effects of
dabigatran, while the non-activated PCCs are likely less effective [31]. This same study also
failed to show benefit of rVIIa for preventing hematoma expansion [31]. Conversely, a rat tail
incision bleeding model suggested that rVIIa did reduce bleeding time [32]. However, there
was no demonstrable positive effect on thrombin time, aPTT, or ecarin clotting time [33].
Similar results were found with both three and four factor PCC [19].
In summary, medical therapy for treatment of dabigatran associated traumatic ICH is some‐
what limited by both a paucity of data and lack of consistent effectiveness demonstrated in
what data does exist. Therefore, supportive therapies such as activated charcoal and dialysis
may be the most prudent approach. Activated charcoal can be effective in reducing therapeutic
levels of dabigatran if the ingestion was relatively recent [34] and dialysis is both pharmaco‐
logically plausible and has been shown to reduce dabigatran levels [22, 35].
3.2. Rivaroxaban
Rivaroxaban is an oral direct factor Xa inhibitor approved for the prophylaxis of deep vein
thrombosis (DVT) post total knee or hip replacement [36], the treatment of DVT or pulmonary
embolus (PE) [37, 38] as well as to reduce the risk of stroke in patients with nonvalvular atrial
fibrillation [39]. The drug reaches maximum concentration within 2 to 4 hours of intake and
has a 5 to 9 hour half-life [40]. Unlike dabigatran, rivaroxaban is highly protein-bound making
it unlikely to be dialyzable [41].
Animal data suggest at most a moderate effect of rVIIa on reversing the anticoagulant effect
of rivaroxaban. In a rat mesenteric bleeding model, this drug decreased the bleeding time, but
had no effect on the inhibited factor Xa activity [42]. A primate model demonstrated a much
less robust effect [43]. In another animal study, a four-factor PCC reversed the effect of
rivaroxaban [44]. The same study by Eerenberg quoted above in regard to dabigatran sug‐
gested that the four factor PCC Cofact may have a positive effect on normalizing the inhibition
of endogenous thrombin potential and the elevated PT induced by rivaroxaban [30]. In a
randomized crossover ex vivo study in healthy volunteers, Marlu et al were able to demonstrate
that the anticoagulant effect of rivaroxaban could be corrected with PCC or FEIBA and that
rVIIa was much less effective [31]. This suggests that PCC may be effective for treating
rivaroxaban-associated traumatic intracranial hemorrhage.
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3.3. Apixaban
Apixaban is an oral factor Xa inhibitor indicated for the prevention of systemic embolism and
stroke in patients with nonvalvular atrial fibrillation. It is the newest agent to be approved for
use. In studies, the major bleeding event rate was approximately 2% compared with warfar‐
in’s 3% rate [49, 73]. The drug requires a dosage adjustment in renal impairment. It is also highly
protein-bound and therefore not dialyzable. Activated charcoal is felt to be a potential interven‐
tion that could be employed early after ingestion, if possible [45]. There are no studies or case
reports in the literature regarding treatment of apixaban-associated bleeding. Therefore, a
similar approach to that used in treating rivaroxaban-associated bleeding is probably reasona‐
ble. However, in a rabbit model, bleeding induced by apixaban was not improved with either
rFVIIa, PCC or fibrinogen [46]. Hopefully, with time and experience, we will learn more about
treating life-threatening bleeding associated with this and the other novel anticoagulants.
4. Other agents to be considered for the treatment of traumatic ICH in the
anticoagulated patient
4.1. rVIIa
Recombinant activated factor VII (rFVIIa) is indicated for hemophilia with inhibitors [47]. But
it has also been used off-label for hemostasis in acute bleeding, surgical bleeding, trauma and
ICH [48, 49, 50]. It has also been used as a medication to assist in hemostatic control of
hemorrhage in trauma [51-56]. While this intervention has been shown to not impact mortality,
it was shown to decrease overall blood product use [57].
rFVIIa works in the presence of tissue factor from injured or ischemic vascular subendothelium
to promulgate clot formation as well as binding directly to platelets and enhancing thrombin
burst to improve clot stability [58].
There is some concern that this agent may increase thromboembolic events [59, 60], particularly
arterial thromboses [61] which tempers enthusiasm for using this agent. Its widespread use
without compelling clinical evidence to do so as well as its substantial cost is concerning as
well [62]. Combining these facts with the modest data available to suggest benefit in treating
ICH in anticoagulated patients, there are likely better treatments except in unusual circum‐
stances.
4.2. Summary
There is limited guidance in the literature to organize a clinical strategy for addressing the
difficult problem of traumatic ICH in anticoagulated patients. However, what is available can
be used to generate a reasonable strategy for treating this patient population, as some institu‐
tions have done (See Appendix 1). For warfarin-associated bleeding, the data and experience
is much more robust. Unfortunately, clinical data is severely lacking on how to treat the patient
population that has been taking one of the novel anticoagulants: dabigatran, rivaroxaban or
apixaban. All of these patients should receive standard neurocritical care supportive measures
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– airway protection, hemodynamic support with IVF and vasopressors, neurosurgical
evaluation as well as discontinuing the patient’s anticoagulant. Depending on the agent
responsible for the patient’s coagulopathy, some of the following may be indicated: activated
charcoal, four-factor protein complex concentrate with or without vitamin K and hemodialy‐
sis/hemoperfusion (dabigatran only). FFP and rVIIa could be options, but these agents may
potentially introduce unnecessary risk, namely transfusion-associated risks with FFP and
thrombosis risk in the case of rVIIa [19]. It is possible that in the future, other agents such as
aminocaproic acid [63, 64] may be discovered to have a role. For now, clinicians are left to rely
on published guidelines from many professional organizations (outlined below) [11, 65-67, 70]
to help the clinician sort through the multiple issues that need to be taken into consideration
when attempting to reverse the effects of systemic anticoagulation in an attempt to limit the
potentially substantial morbidity and mortality of traumatic brain injury in the anticoagulated
patient.
	
	
	
	
	
Patients	with	ICH	whose	INR	is	elevated	due	to	oral	anticoagulants	should	have	their	warfarin	withheld,	receive	therapy	to	replace	vitamin	K‐dependant	factors	and	correct	the	INR,	and	receive	IV	vitamin	K	(ClassI;	Level	of	Evidence:		C).Prothrombin	complex	concentrates	have	not	shown	improved	outcome	compared	with	FFP	but	may	have	fewer	complications	compared	with	FFP	and	are	reasonable	to	consider	as	an	alternative	to	FFP	(Class	IIa;	Level	of	Evidence:		B).
American	Stroke	Association	(70)
For	warfarin‐associated	major	bleeding,	rapid	reversal	of	anticoagulation	with	four‐factor	prothrombin	complex	concetrate	is	suggested	rather	than	plasma.		(Grade	2C).
Suggest	additional	use	of	vitamin	K	5‐10mg	administered	by	slow	IV	injection	rather	than	reversal	with	coagulation	factors	alone.		(Grade	2C)
American	College	of	Chest	Physicians	(ACCP)	(11)
For	life	threatening	bleeding	associated	with	dabigatran,	hemodialysis	is	a	therapeutic	option.
Direct	factor	Xa	inhibitors	could	be	partially	antagonised	by	non‐activated	four‐factor	PCC	at	a	dose	of	50u/kg.	
Italian	Federation	of	Thrombosis	Centers(66)
For	urgent	reversal	of	warfarin,	5‐10mg	of	IV	vitamin	K	and	PCC	or	FFP	should	be	given.
For	urgent	reversal	of	dabigatran	in	a	patient	with	a	prolonged	aPTT,	PCC,	FEIBA,	rFVIIa	or	hemodialysis	should	be	considered.
American	Society	of	Hematology(65)
For	moderate	to	severe	bleeding	associated	with	dabigatran,	consider:‐ Tranexamic	acid	15‐30mg/kg	IV	x	1,	possible	continuous	infusion	1mg/kg/hr.‐ Charcoal	if	taken	<2hr	prior	to	presentation‐ Prothrombinex‐VF	25‐50u/kg
For	life‐threatening	bleeding	associated	with	dabigatran,	consider:‐ interventions	outlined	for	moderate/severe	bleeding‐ rVIIa	100mcg/kg	IV
Pharmaceutical	Management	Agency.		The	Government	of	New	Zealand.(67)
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Appendix 1
Mercy Hospital St. Louis Trauma/Neuro ICU
Anticoagulant reversal protocol
This is the reversal protocol for a patient who has an intracranial hemorrhage and is taking
one of the agents listed below. If the patient has had a cardiac ischemic event or other throm‐
boembolic event within the last 30 days, the risks and benefits of PCCs, which have a higher
rate of thrombotic events, over an FFP-based protocol should be weighed and clinical judge‐
ment should be applied.
If INR is 1.5-2.0 only FFP protocol should be utilized as Kcentra is not approved for reversal
of warfarin in this INR range.
1. WARFARIN- Related ICH- using PCCs (Kcentra):
Warfarin with: INR < 1.2Recheck PT/INR in 12 hours
INR 1.2 – 1.4 Give Vitamin K 5 mg IV over 30 minutes if not already given and recheck
PT/INR in 12 hours.
INR 1.5-1.9Use FFP protocol. Please dose based on weight and INR (See dosing Table 2]
INR ≥ 2.0 Give Vitamin K 10 mg IV over 30 minutes if not already given. Give Kcentra based
on the table (see below). Recheck PT/INR 20 minutes after infusion complete. Treat again based
on INR level.
Pre-treatment INR 2- <4 4-6 >6
Dose of Kcentra (Units of Factor
IX)/kg body weight 25 35 50
Maxiumum dose (Units of Factor
IX) Not to exceed 2500 Not to exceed 3500 Not to exceed 5000
Table 2.
2. WARFARIN- Related ICH- using FFP:
If the patient has had a recent MI or other thromboembolic event and the decision is to not
use PCCs, then consider using FFP according to the following calculations:
Warfarin with: INR < 1.2Recheck PT/INR in 12 hours
INR 1.2 – 1.4 Give Vitamin K 5 mg IV over 30 minutes if not already given and recheck
PT/INR in 12 hours.
INR > 1.5Give Vitamin K 10 mg IV over 30 minutes if not already given. Give FFPs based on
the table (see below). Recheck PT/INR 20 minutes after infusion complete. Treat again based
on INR level.
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INR Fresh Frozen Plasma Dose by Weight (kg)
Less Than 75 kg 75-100 kg Greater than 100 kg
1.5-2.5 2 units 4 units 6 units
2.6-3.5 3 units 5 units 7 units
3.6-5 4 units 6 units 8 units*
Greater than 5 6 units 8 units* 10 units*
Table 3.
This document is intended as a guide to the correct adult dose of FFP, it is not a directive, and
should not be used in place of clinical assessment.
*Caution should be exercised if using this chart for calculating FFP volumes for overweight
patients as the volume suggested may be an over estimation and may risk fluid overload.
HEPARIN- Related ICH:
Reversal of Intravenous Heparin-Related Intracerebral Hemorrhage
Immediately stop heparin source
Protamine dosing for reversal of intravenous heparin
Time Elapsed Protamine dose
Immediate 1 mg per 100 units of heparin
30-60 minutes 0.5 mg per 100 units of heparin
Greater than 2 hours but less than 4 hours 0.25 mg per 100 units of heparin
Protamine _____ mg (maximum dose 50 mg) intravenous over 10 minutes.
Table 4.
3. ENOXAPARIN- Related ICH:
If taken within 24 hours (full dose only, no treatment is indicated for prophylactic doses of
LMWH), give 1 mg protamine for every 1 mg of enoxaparin which was given up to a maximum
dose of 50 mg. If another LMWH compound was given, please contact the pharmacy to discuss
the protamine dosing.
4. tPA- Related ICH:
Immediately stop the thrombolytic infusion.
Send PT/PTT, platelet count, fibrinogen level, and type and cross.
Transfusions should begin while waiting for lab results.
Transfuse 6 pack of platelets.
Transfuse ______ units of cryoprecipitate (recommend 0.1-0.2 units/kg).
Consider giving aminocaproic acid (Amicar) 5 grams/250 cc NS IV over 60 minutes.
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Once initial lab results return, calculate the amount of fibrinogen needed to achieve a level of
> 150 mg/dl (one unit of cryoprecipitate increases fibrinogen by 7-10 mg/dl). This second dose
should equal the total amount needed minus the initial dose.
Recheck CBC, PT/PTT, and fibrinogen one hour after transfusion therapy is completed.
Management of Bleeding in Patients
Taking Dabigatran/ Rivaroxaban/ Apixaban
	
	 	 	 	 		
	 	 	 	
												*Preferred	Regimen								 		
	
	
 Control	bleeding	with	local	hemostatic	measures	
 Initiate	appropriate	resuscitation	measures	
 Insure	adequate	urine	output	
 STOP	dabigatran/	rivaroxaban/	apixaban	and	record	time	of	last	dose	
 Order	STAT	CBC,	BMP,	fibrinogen	
AND	
Dabigatran	 	 	 	 Rivaroxaban/	Apixaban	
 STAT	aPTT	and	Thrombin	Time	 	 	 	 	 	 STAT	PT/	INR	
Major	bleeding
Minor	Bleeding	
 Conservative	management	
 Activated	charcoal	25g	PO/NG	IF	last	dose	received	within	2hr	of	presentation	
Dabigatran	
 Consider	urgent	hemodialysis*	
o Strongly	consider	if	aPTT	elevated		
 Consider	rF	VIIa	90mcg/kg	IVx1	dose,	repeat	x1	in	2hr	if	needed	
 Consider	platelet	transfusion	if	pt	also	taking	anti‐platelet	medications	
Rivaroxaban/	Apixaban	
 Consider	KCENTRA	50u/kg	IV	x1	dose	
 Consider	rF	VIIa	90	mcg/kg	IV,	repeat	x1	in	2hr	if	needed	
 Consider	platelet	transfusion	if	pt	also	taking	anti‐platelet	medications	
1) Van	Ryn	J,	Stangier	J,	Haertter	S,	Liesenfeld	K,	Wienen	W,	Feuring	M,	Clemens	A.	Dabigatran	Etexilate	–	A	Novel,	Reversible,	Oral	Direct	Thrombin	Inhibitor:	Interpretation	of	Coagulation	Assays	and	Reversal	of	Anticoagulant	Activity.	Thrombosis	and	Haemostasis.	2010;103:1116	
2) Sattari	M,	Lownthal	DT.	Novel	Oral	Anticoagulants	in	Development:	Dabigatran,	Rivaroxaban,	and	Apixaban.	Am	J	Therapeutics.	2011;18:332	
3) Watanage	M,	Siddiqui	FM,	Qureshi	A.	Incidence	and	Management	of	Ischemic	Stroke	and	Intracerebral	Hemorrhage	in	Patients	on	Dabigatran	Etexliate	Treatment.	Neurocrit	Care.	Published	online	7/12/11.	
4) Erenberg	ES,	Kamphuisen	PW,	Sijpkens	MK,	Meigers	JC,	Buller	HR,	Levi	M.	Reversal	of	Rivaroxaban	and	Dabigatran	by	Prothrombin	Complex	Concentrate,	A	Randomized,	Placebo‐Controlled,	Crossover	Study	in	Healthy	Subjects.	Circulation.	2011;124:1573	
5) Battinelli	EM.	Reversal	of	New	Oral	Anticoagulants.	Circulation.	2011;124:1508	
6) Samama	CM.	Prothrombin	Complex	Concentrates:	A	Brief	Review.	European	Journal	of	Anaesthesiology.	2008;25:784	
7) Patanwala	AE,	Acquisto	NM,	Erstad	BL.	Prothrombin	Complex	Concentrate	for	Critical	Bleeding.	Annals	of	Pharmacotherapy.	2011;45:990	
8) Bershad	EM,	Suarez	JI.	Prothrombin	Complex	Concentrates	for	Oral	Anticoagulant	Therapy‐Related	Intracranial	Hemorrhage:	A	Review	of	the	Literature.	Neurocrit	Care.	Published	online	12/5/2009	
9) Ingerslev	J,	Vanek	T,	Culic	S.	Use	of	Recombinant	Factor	VIIa	for	Emergency	Reversal	of	Anticoagulation.	J	Postgrad	Med.	2007;53:1		
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